H.C. Wainwright raises Kodiak Sciences stock price target on trial data
H.C. Wainwright raised its price target on Kodiak Sciences (NASDAQ:KOD) to $126 from $96, maintaining a Buy rating. The move follows positive Phase 3 DAYBREAK trial results for Zenkuda and Tabirafusp in wet age-related macular degeneration. The trial met its primary endpoint, with Zenkuda showing sustained efficacy. Kodiak plans to submit a Biologics License Application in Q4 2026. The stock is up 741% over the past year, trading at $99.87. Other analysts have mixed outlooks on the company.
How this was made
The 30-second read
Why it matters
The upgraded target and trial data provide a fresh catalyst that could move KOD shares higher in the short term.
Market read
Positive trial data and a higher price target create a near‑term buying opportunity for KOD.
What to watch
Potential regulatory delays and competition from established anti‑VEGF agents could temper upside.
Background
The article reports analyst price‑target revisions following the presentation of Phase 3 DAYBREAK trial results at the 2026 AAO meeting.
Ticker impact
H.C. Wainwright raised its price target on Kodiak Sciences after Phase 3 DAYBREAK trial data showed non‑inferior efficacy and six‑month dosing durability.
likely upward pressure as investors price in improved efficacy and upcoming BLA filing.
Analyst upgrade based on fresh Phase 3 data and a new $126 target creates a clear catalyst for near‑term buying.
Market effects
Strengthens the ophthalmology biotech sub‑sector and may lift peers with similar AMD pipelines.
U.S. biotech market could see modest gains as investors reassess AMD therapeutic candidates.
Limited to biotech investors; no broad market impact.
Counterpoint
Some analysts remain cautious, noting the trial only met non‑inferiority and the target remains below prior highs.
Key entities
- companyKodiak Sciences Inc.
Biopharma developing treatments for wet age‑related macular degeneration.
- analystH.C. Wainwright
Equity research firm that raised its price target on KOD.
